EMALEX BIOSCIENCES, INC.
Emalex Biosciences is a biopharmaceutical company dedicated to the development of new and novel treatments for patients with central nervous system disorders who have limited or no treatment options.
EMALEX BIOSCIENCES, INC.
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2018-01-01
Address:
Northbrook, Illinois, United States
Country:
United States
Website Url:
http://www.emalexbiosciences.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
35 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Global Site Tag WPForms
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-08-14 | Paragon Biosciences | Paragon Biosciences acquired by Emalex Biosciences, Inc. | N/A |
Investors List
Paragon Biosciences
Paragon Biosciences investment in Series C - Emalex Biosciences, Inc.
Valor Equity Partners
Valor Equity Partners investment in Series C - Emalex Biosciences, Inc.
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series C - Emalex Biosciences, Inc.
Official Site Inspections
http://www.emalexbiosciences.com Semrush global rank: 3.24 M Semrush visits lastest month: 5.12 K
- Host name: 248.67.209.35.bc.googleusercontent.com
- IP address: 35.209.67.248
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Emalex Biosciences, Inc."
ABOUT US - Emalex Biosciences
Our leadership team is comprised of remarkable professionals who are passionate about innovative solutions that improve the lives of people living with chronic central nervous system conditions.See details»
Emalex Biosciences - Crunchbase Company Profile
Contact Email [email protected] Emalex Biosciences is a biotech startup that develops new treatments for central nervous system disorders. …See details»
Emalex Biosciences - LinkedIn
Emalex Biosciences was created by Paragon Biosciences to solve unmet needs for patients with central nervous system disorders. From discovery to development, the Emalex team advanced …See details»
Emalex Biosciences - Overview, News & Similar companies
Emalex Biosciences contact info: Phone number: (312) 847-1340 Website: www.emalexbiosciences.com What does Emalex Biosciences do? Emalex Biosciences is a …See details»
Emalex Biosciences Company Profile - Office Locations ... - Craft
Emalex Biosciences has 5 employees at their 1 location and $35 m in total funding,. See insights on Emalex Biosciences including office locations, competitors, revenue, financials, executives, …See details»
Emalex Biosciences Company Overview, Contact Details
Nov 3, 2022 Award-Winning Recognition Emalex Biosciences has been awarded 'Neuroscience Therapeutics Company of the Year,' showcasing its industry leadership and innovative …See details»
Emalex Biosciences
For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders. At Emalex Biosciences, we are working diligently …See details»
Emalex Biosciences - 2025 Company Profile - Tracxn
May 11, 2025 Emalex Biosciences - Developer of therapeutics for the treatment of rare and orphan neurological conditions. Raised a total funding of $285M over 3 rounds from 5 …See details»
Emalex Biosciences - PitchBook
Emalex Biosciences General Information Description. Developer of biopharmaceutical drugs designed to diagnose and cure central nervous system disorders and rare and orphan …See details»
Emalex Biosciences, Inc. - Drug pipelines, Patents, Clinical trials ...
Www.emalexbiosciences.com. Startups | Holding Company | 2018 | Illinois, United States | 10-50 | www.emalexbiosciences.com. Last update 08 Mar 2025. Overview. Pipeline. Deal. ... The …See details»
Emalex Biosciences Announces $250 Million Financing Round to …
Nov 3, 2022 Emalex Biosciences was created by Paragon Biosciences to develop new treatments for central nervous system disorders. Emalex is in late-stage development of a new …See details»
Emalex Biosciences - Bain Capital Life Sciences
Emalex Biosciences was created by Paragon Biosciences to develop new treatments for central nervous system disorders. Emalex is in late-stage development of a new class of drug …See details»
CAREERS - Emalex Biosciences
Careers Careers We're a mission-driven team committed to improving the lives of patients with central nervous system disorders. Here, every voice is valued, collaboration is second nature, …See details»
Emalex Biosciences - workinbiotech.com
Emalex Biosciences is developing innovative treatments for central nervous system (CNS) disorders. Their primary areas of research focus are on Restless Leg Syndrome and Tourette …See details»
Research & Development - Emalex Biosciences
Therapeutic Focus: Emalex is focused on central nervous system movement disorders and fluency disorders. Our current focus is developing ecopipam, an investigational medicine, for …See details»
Emalex Biosciences CEO and Key Executive Team | Craft.co
Emalex Biosciences's Chief Business Officer is Eric Messner. Other executives include Atul R. Mahableshwarkar, Chief Medical Officer and Senior Vice President of Drug Development; Jay …See details»
Emalex Biosciences Named “Neuroscience Therapeutics Company …
Feb 27, 2025 CHICAGO, February 25, 2025 – Emalex Biosciences announced positive topline data from its Phase 3 registrational study of ecopipam, a novel dopamine-1 receptor …See details»
Emalex Biosciences Named “Neuroscience Therapeutics Company …
Nov 19, 2024 Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industries CHICAGO, November 19, 2024 – Emalex Biosciences was named …See details»
News - Emalex Biosciences
Topline data from Phase 3 study in patients with Tourette syndrome shows statistical significance between ecopipam and placebo for both the primary efficacy endpoint in pediatric subjects (p …See details»
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary ...
Feb 25, 2025 Topline data from Phase 3 study in patients with Tourette syndrome shows statistical significance between ecopipam and placebo for both the primary efficacy endpoint in …See details»